Orphazyme AS (STU:1TB0) Interest Expense : €-1.27 Mil (TTM As of Jun. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Orphazyme AS Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Orphazyme AS's interest expense for the six months ended in Jun. 2022 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2022 was €-1.27 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Orphazyme AS's Operating Income for the six months ended in Jun. 2022 was € -3.67 Mil. Orphazyme AS's Interest Expense for the six months ended in Jun. 2022 was € 0.00 Mil. Orphazyme AS has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Orphazyme AS Interest Expense Historical Data

The historical data trend for Orphazyme AS's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Interest Expense Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Interest Expense

Get a 7-Day Free Trial

-0.09

-0.38

-0.64

-1.90

-1.27

Orphazyme AS Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Interest Expense	Get a 7-Day Free Trial									-1.07	-0.83	-	-1.27	-

Orphazyme AS Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.27 Mil.

Orphazyme AS (STU:1TB0) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Orphazyme AS's Interest Expense for the six months ended in Jun. 2022 was €0.00 Mil. Its Operating Income for the six months ended in Jun. 2022 was €-3.67 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2022 was €0.00 Mil.

Orphazyme AS's Interest Coverage for the quarter that ended in Jun. 2022 is calculated as

Orphazyme AS had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Orphazyme AS (STU:1TB0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (STU:1TB0) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (STU:1TB0) Headlines

No Headlines